Mechanism of action and bioactivation
Calcitriol is the end product of a complex cascade of metabolic transformations. To understand its pharmacological value, one must examine the natural activation pathway of vitamin D in the body, which occurs in two stages (via hydroxylation):
- Hepatic stage: The initial substrate of animal origin — cholecalciferol (the inactive form, vitamin $D_3$) — is converted by the enzyme 25-hydroxylase into calcidiol (25(OH)$D_3$). This is the transport form, but it is still inactive.
- Renal stage: Calcidiol is carried by the bloodstream to the kidneys, where the enzyme 1-hydroxylase converts it into calcitriol (1,25(OH)$_2D_3$). This substance is the true active form.
For these reactions to proceed normally under natural conditions, ultraviolet irradiation (sunlight) and normal hepatic and renal enzyme activity are required. By prescribing the ready-made drug Calcitriol, the physician allows the patient to "bypass" both stages of bioactivation. This is critically important if the patient has impaired synthesis of their own active forms.
Pharmacological effects
The drug's action is closely linked to the physiological effects of parathyroid hormone (PTH). Normally, PTH stimulates the production of endogenous calcitriol. In turn, calcitriol duplicates and enhances the effects of PTH aimed at increasing plasma calcium concentration.
Main mechanisms for increasing calcium levels:
- In the intestine: Mediated increase in dietary calcium absorption (one of the main effects of active vitamin D).
- In the kidneys: Reduction of urinary calcium excretion by enhancing its reabsorption in the renal tubules.
- In bone tissue: Stimulation of osteoclast activity, leading to the mobilization (release) of calcium from "bone depots" into the systemic circulation.
Clinical significance and indications
The synthesis of active forms of vitamin D in the body can decline under the influence of three main factors: lack of sun exposure, liver diseases, and, most commonly, renal pathologies.
Impaired 1-hydroxylation in the kidneys is a key cause in the development of osteopenia and osteoporosis. This is particularly relevant in renal failure, during menopause, or against the background of long-term steroid therapy. In these cases, replacement therapy with ready-made calcitriol is indicated.
In childhood, a deficiency of active metabolites leads to serious developmental disorders. Clinical manifestations include:
- Delayed closure of the fontanelles;
- Late teething;
- Bone skeletal deformities;
- Pronounced muscle weakness.
Prescription writing rules
The drug is available in oral capsules. Dosages are microscopic, so when writing a prescription, extreme care must be taken with zeros to avoid overdose.
Available forms: 0.00025 g and 0.005 g capsules. The oral dosage range is 0.00025–0.005 g.
Example of a prescription form for the minimum dosage: Rp.: Caps. Calcitrioli 0.00025 D.t.d. N. 30 S. Take 1 capsule orally.
Briefly: answers to topical questions
In which diseases is the prescription of calcitriol indicated?
The prescription of active vitamin D metabolites, including calcitriol, is indicated in end-stage chronic renal failure, hypoparathyroidism, and pseudohypoparathyroidism as absolute indications. Relative indications include chronic kidney disease with a glomerular filtration rate below 60 mL/min, age over 65 years, and high risk. Therapy is also used in patients with chronic kidney disease with persistent intact parathyroid hormone levels above target values.
What side effects are characteristic of calcitriol preparations?
Calcitriol preparations carry the risk of increasing blood calcium concentration and developing hypercalcemia.
What are the absolute contraindications to the use of calcitriol?
Hypercalcemia is listed as a contraindication for the use of vitamin D receptor activators, including calcitriol.
CalciTRIol — THREE target organs for increasing calcium: intestine (absorption), kidneys (reabsorption), bones (mobilization).
Class and exam questions
Why does osteoporosis develop in chronic renal failure?
The kidneys contain the enzyme 1-hydroxylase, which converts inactive calcidiol into active calcitriol. In renal pathology, this process is disrupted, leading to a deficiency of active vitamin D, which results in impaired phosphorus-calcium metabolism and bone mass loss.
How does calcitriol differ from cholecalciferol?
Cholecalciferol is an inactive form of vitamin D3 of animal origin that requires two stages of activation (in the liver and kidneys). Calcitriol is already a ready-made active metabolite that acts immediately.
How does parathyroid hormone interact with calcitriol?
Parathyroid hormone increases the level of calcitriol in the body. Together, they act as synergists regarding blood calcium levels, duplicating each other's effects (enhancing intestinal absorption, renal reabsorption, and bone mobilization).
What else to study on this topic
- Differences between plant provitamin (ergocalciferol) and animal provitamin (cholecalciferol).
- The role of hepatic 25-hydroxylase in forming the transport form — calcidiol.
- Antagonism of calcium and plasma phosphates under the action of parathyroid hormone.
- Calcitonin preparations (e.g., calcitrine) as physiological antagonists that suppress osteoclasts and lower calcium levels.
- Symptoms of hypercalcemia as the main potential complication of vitamin D active form overdose.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Calcitriol" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.